Immunovant to host an investor webcast to announce two new indications for their investigational product candidate, batoclimab (IMVT-1401). The event will feature prepared remarks by company management and external key opinion leaders in the autoimmune disease space.

Batoclimab (IMVT-1401), is a novel, fully human monoclonal antibody targeting the neonatal Fc receptor (FcRn).

A live question and answer session with Immunovant management will follow.